These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 24431399)

  • 1. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.
    Kuo CF; Grainge MJ; Mallen C; Zhang W; Doherty M
    Ann Rheum Dis; 2015 Apr; 74(4):661-7. PubMed ID: 24431399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and management of gout in Taiwan: a nationwide population study.
    Kuo CF; Grainge MJ; See LC; Yu KH; Luo SF; Zhang W; Doherty M
    Arthritis Res Ther; 2015 Jan; 17(1):13. PubMed ID: 25612613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and prevalence of gout in Western Sweden.
    Dehlin M; Drivelegka P; Sigurdardottir V; Svärd A; Jacobsson LT
    Arthritis Res Ther; 2016 Jul; 18():164. PubMed ID: 27412614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
    Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
    Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate-lowering treatment and risk of total joint replacement in patients with gout.
    Kuo CF; Chou IJ; See LC; Chen JS; Yu KH; Luo SF; Hsieh AH; Zhang W; Doherty M
    Rheumatology (Oxford); 2018 Dec; 57(12):2129-2139. PubMed ID: 30060176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
    Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
    [No Abstract]   [Full Text] [Related]  

  • 8. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
    Hakoda M; Kasagi F
    Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
    [No Abstract]   [Full Text] [Related]  

  • 9. Cohort study investigating gout flares and management in UK general practice.
    Finnikin S; Mallen CD; Roddy E
    BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.
    Rai SK; Aviña-Zubieta JA; McCormick N; De Vera MA; Shojania K; Sayre EC; Choi HK
    Semin Arthritis Rheum; 2017 Feb; 46(4):451-456. PubMed ID: 28040245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary epidemiology of gout in the UK general population.
    Cea Soriano L; Rothenbacher D; Choi HK; García Rodríguez LA
    Arthritis Res Ther; 2011 Mar; 13(2):R39. PubMed ID: 21371293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
    Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
    Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
    Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
    Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration.
    Helget LN; England BR; Roul P; Sayles H; Petro AD; Michaud K; Mikuls TR
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1363-1371. PubMed ID: 32475070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016.
    Tsoi MF; Chung MH; Cheung BMY; Lau CS; Cheung TT
    Arthritis Res Ther; 2020 Sep; 22(1):204. PubMed ID: 32887668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with initiation and persistence of urate-lowering therapy.
    Dehlin M; Ekström EH; Petzold M; Strömberg U; Telg G; Jacobsson LT
    Arthritis Res Ther; 2017 Jan; 19(1):6. PubMed ID: 28095891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
    Lin KH; Yen FS; Li HL; Wei JC; Hsu CC; Yang CC; Hwu CM
    J Hum Hypertens; 2021 Apr; 35(4):351-359. PubMed ID: 32366929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
    Robinson PC; Taylor WJ; Dalbeth N
    J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.